Tenax Therapeutics, Inc. (TENX)
Health Care ยท Pharmaceutical Preparations
Tenax Therapeutics, Inc. (TENX) is listed on Nasdaq, where its shares have traded since February 1, 1995. SentiSense covers Tenax Therapeutics, Inc. in the Health Care sector, and its Standard Industrial Classification is Pharmaceutical Preparations. Christopher T. Giordano is its chief executive officer. The company reports 16 employees, and its corporate website is www.tenaxthera.com.
About Tenax Therapeutics, Inc.
Tenax Therapeutics Inc is a phase three, development-stage pharmaceutical company focused on identifying and developing therapeutics that address cardiovascular and pulmonary diseases with high unmet medical need, with an initial therapeutic focus on pulmonary hypertension. Its drug development pipeline comprises: Levosimendan, a novel, first-in-class K-ATP activator and calcium sensitizer developed for intravenous use in hospitalized patients with acutely decompensated heart failure; and Imatinib, as a potential therapy for pulmonary arterial hypertension. The company is currently conducting clinical trials only for levosimendan as its prioritized product candidate to evaluate its potential to help patients with pulmonary hypertension.
Latest reported results
Tenax Therapeutics, Inc. reported revenue of $0.00 for Q2 FY2026.
Institutional ownership
In 13F filings for the quarter ended June 30, 2026, 108 institutions reported holding TENX, with 30.3 million shares worth $441.4 million in aggregate. The largest reported holders were FMR, Vivo Capital and BlackRock. Of the 5 largest reported holders, all 5 added shares during the quarter.
More on TENX
- TENX sentiment: whether news and social coverage of Tenax Therapeutics, Inc. leans bullish or bearish, and the stories driving it.
- TENX ownership: all 108 reporting institutions, plus insider and congressional trades.
- TENX financials: revenue, net income, operating margin and free cash flow through Q2 FY2026.
SentiSense also tracks daily options readings for Tenax Therapeutics, Inc.: IV rank, put/call percentile, 25-delta skew and open-interest walls.
Frequently asked questions
What does Tenax Therapeutics, Inc. do?
Tenax Therapeutics Inc is a phase three, development-stage pharmaceutical company focused on identifying and developing therapeutics that address cardiovascular and pulmonary diseases with high unmet medical need, with an initial therapeutic focus on pulmonary hypertension.
What sector is TENX in?
SentiSense classifies Tenax Therapeutics, Inc. in the Health Care sector, and its Standard Industrial Classification is Pharmaceutical Preparations.
Where does TENX stock trade?
Tenax Therapeutics, Inc. (TENX) is listed on Nasdaq, where its shares have traded since February 1, 1995.
Who is the CEO of Tenax Therapeutics, Inc.?
Christopher T. Giordano is the chief executive officer of Tenax Therapeutics, Inc..